NORD

Norda OTCNO:NORD Stock Report

Last Price

kr41.00

Market Cap

kr208.7m

7D

0%

1Y

n/a

Updated

15 May, 2022

Data

Company Financials
NORD fundamental analysis
Snowflake Score
Valuation5/6
Future Growth0/6
Past Performance2/6
Financial Health4/6
Dividends3/6

NORD Stock Overview

Norda ASA, a biotechnology company, engages in the cancer diagnostic activities.

Norda Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Norda
Historical stock prices
Current Share Pricekr41.00
52 Week Highkr0
52 Week Lowkr0
Beta0.30
1 Month Change0%
3 Month Change0%
1 Year Changen/a
3 Year Change127.78%
5 Year Change382.35%
Change since IPO-99.59%

Recent News & Updates

Shareholder Returns

NORDNO BiotechsNO Market
7D0%-6.1%-1.2%
1Yn/a-48.9%12.6%

Return vs Industry: Insufficient data to determine how NORD performed against the Norwegian Biotechs industry.

Return vs Market: Insufficient data to determine how NORD performed against the Norwegian Market.

Price Volatility

Is NORD's price volatile compared to industry and market?
NORD volatility
NORD Average Weekly Movementn/a
Biotechs Industry Average Movement8.9%
Market Average Movement7.4%
10% most volatile stocks in NO Market12.4%
10% least volatile stocks in NO Market4.2%

Stable Share Price: Insufficient data to determine NORD's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine NORD's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
20021Frode Westvoldhttps://www.nordasa.no

Norda ASA, a biotechnology company, engages in the cancer diagnostic activities. The company is involved in the research and development of Genefec, a diagnostic screening test for colorectal cancer. It also invests and trades in securities, real estates, and other assets.

Norda Fundamentals Summary

How do Norda's earnings and revenue compare to its market cap?
NORD fundamental statistics
Market Capkr208.70m
Earnings (TTM)kr427.66m
Revenue (TTM)kr469.05m

0.5x

P/E Ratio

0.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NORD income statement (TTM)
Revenuekr469.05m
Cost of Revenuekr0
Gross Profitkr469.05m
Other Expenseskr41.39m
Earningskr427.66m

Last Reported Earnings

Dec 31, 2020

Next Earnings Date

n/a

Earnings per share (EPS)84.01
Gross Margin100.00%
Net Profit Margin91.17%
Debt/Equity Ratio303.5%

How did NORD perform over the long term?

See historical performance and comparison

Dividends

14.6%

Current Dividend Yield

7%

Payout Ratio

Valuation

Is Norda undervalued compared to its fair value and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: NORD (NOK41) is trading below our estimate of fair value (NOK162.05)

Significantly Below Fair Value: NORD is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: NORD is good value based on its PE Ratio (0.5x) compared to the European Biotechs industry average (40x).

PE vs Market: NORD is good value based on its PE Ratio (0.5x) compared to the Norwegian market (13.1x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NORD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NORD is good value based on its PB Ratio (1.4x) compared to the NO Biotechs industry average (3.9x).


Future Growth

How is Norda forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


65.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Norda has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Norda performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


943.3%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: NORD has a high level of non-cash earnings.

Growing Profit Margin: NORD's current net profit margins (91.2%) are higher than last year (48.2%).


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if NORD's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare NORD's past year earnings growth to its 5-year average.

Earnings vs Industry: NORD earnings growth over the past year (943.3%) exceeded the Biotechs industry -5.2%.


Return on Equity

High ROE: Whilst NORD's Return on Equity (288.82%) is outstanding, this metric is skewed due to their high level of debt.


Financial Health

How is Norda's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: NORD's short term assets (NOK563.6M) exceed its short term liabilities (NOK481.4M).

Long Term Liabilities: NORD has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: NORD has more cash than its total debt.

Reducing Debt: NORD's debt to equity ratio has increased from 77.9% to 303.5% over the past 5 years.

Debt Coverage: NORD's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: NORD's interest payments on its debt are well covered by EBIT (72.9x coverage).


Balance Sheet


Dividend

What is Norda current dividend yield, its reliability and sustainability?

Dividend Score

3/6

Dividend Score 3/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


14.63%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: NORD's dividend (14.63%) is higher than the bottom 25% of dividend payers in the Norwegian market (2.9%).

High Dividend: NORD's dividend (14.63%) is in the top 25% of dividend payers in the Norwegian market (6.64%)


Stability and Growth of Payments

Stable Dividend: Too early to tell whether NORD's dividend payments have been stable as they only just started paying a dividend.

Growing Dividend: Too early to tell if NORD's dividend payments are increasing as they only just started paying a dividend.


Earnings Payout to Shareholders

Earnings Coverage: With its low payout ratio (7.1%), NORD's dividend payments are thoroughly covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Insufficient data to calculate cash payout ratio to determine if its dividend payments are covered by cash flows.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Frode Westvold

no data

Tenure

Dr. Frode Westvold, Ph D., serves as Chief Executive Officer and General Manager of Norda ASA. Dr. Westvold serves as Chief Executive Officer and Partner of Andenaesgrupen/AS Tanja.He served as Director o...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.4%.


Top Shareholders

Company Information

Norda ASA's employee growth, exchange listings and data sources


Key Information

  • Name: Norda ASA
  • Ticker: NORD
  • Exchange: OTCNO
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: kr208.701m
  • Shares outstanding: 5.09m
  • Website: https://www.nordasa.no

Number of Employees


Location

  • Norda ASA
  • Stortingsgaten 28
  • Oslo
  • Oslo
  • 161
  • Norway

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/15 00:00
End of Day Share Price2022/05/05 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.